IDH1 and neoplasm: The IDH mutation confers a significant survival benefit to patients with glioma, even in the most aggressive grade 4 astrocytomas (31 months overall survival vs. 15 months survival).6 As all gliomas inevitably recur, longitudinal monitoring is essential to enable early detection of tumor recurrence.